A Simulation Study to Compare New Adaptive Dose–Ranging Designs

The main goals in an adaptive dose-ranging study are to detect dose response, to determine if any doses(s) meets clinical relevance, to estimate the dose-response, and then to decide on the dose(s) (if any) to take into the confirmatory Phase III. Adaptive dose-ranging study designs may result in power gains to detect dose response and higher precision in estimating the target dose and the dose response curve. In this article, we complement the library of available methods with five new adaptive dose-ranging designs. Due to their inherent complexity, the operating characteristics can be assessed only through intensive simulations. We present here results of a comprehensive simulation study that compares and contrasts these designs for a variety of different scenarios.

[1]  Holger Dette,et al.  Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve , 2007, Journal of biopharmaceutical statistics.

[2]  W. Näther.  Optimum experimental designs , 1994 .

[3]  A. Ivanova,et al.  An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose‐finding study , 2009, Statistics in medicine.

[4]  Holger Dette,et al.  Optimality criteria for regression models based on predicted variance , 1999 .

[5]  J. A. Nelder,et al.  Inverse Polynomials, a Useful Group of Multi-Factor Response Functions , 1966 .

[6]  H. Dette,et al.  Response-adaptive dose-finding under model uncertainty , 2011, 1107.5883.

[7]  D. G. Watts,et al.  A Quadratic Design Criterion for Precise Estimation in Nonlinear Regression Models , 1985 .

[8]  Anastasia Ivanova,et al.  Adaptive dose finding based on t‐statistic for dose–response trials , 2008, Statistics in medicine.

[9]  S. Ruberg.  Dose response studies. II. Analysis and interpretation. , 1995, Journal of biopharmaceutical statistics.

[10]  Holger Dette,et al.  Practical considerations for optimal designs in clinical dose finding studies , 2010, Statistics in medicine.

[11]  Sue-Jane Wang,et al.  Discussion of the “White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs” , 2007, Journal of biopharmaceutical statistics.

[12]  Frank Bretz,et al.  Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies , 2010 .

[13]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[14]  José Pinheiro,et al.  Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III , 2010 .

[15]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[16]  G. P. Clarke,et al.  Moments of the Least Squares Estimators in a Non‐Linear Regression Model , 1980 .

[17]  F Bretz,et al.  Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies , 2005, Biometrics.

[18]  Robert Hemmings,et al.  Discussion of “The White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs” , 2007, Journal of biopharmaceutical statistics.

[19]  Brenda Gaydos,et al.  Adaptive Designs in Dose- Finding Studies , 2007 .

[20]  M. J. Box.  Bias in Nonlinear Estimation , 1971 .

[21]  J. Ph,et al.  Dose response studies. II. Analysis and interpretation. , 1995 .

[22]  F. Hsuan,et al.  Adaptive Designs for Dose-Finding Studies Based on Sigmoid E max Model , 2007, Journal of biopharmaceutical statistics.

[23]  Holger Dette,et al.  Optimal Designs for Dose-Finding Studies , 2008 .

[24]  F. Hsuan,et al.  Adaptive Penalized D-Optimal Designs for Dose Finding Based on Continuous Efficacy and Toxicity , 2010 .

[25]  Frank Bretz,et al.  MCPMod: An R Package for the Design and Analysis of Dose-Finding Studies , 2009 .